Neurology Central

Alzheimer’s antibody trial: is a new treatment in sight?

Researchers at the University of Zurich (UZH; Switzerland) have published findings from what could be a landmark clinical trial in the search for effective treatments for Alzheimer’s disease (AD). The new drug on trial, aducanumab, is an antibody that targets beta-amyloid plaques. The team demonstrated a significant reduction in plaques and a slowing in cognitive declined in AD patients treated with the drug, compared to a placebo control group.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.